Marasa lafiya 'yan ƙasar Ostiraliya sun cimma nasarar amsawa da wuri tare da maganin BIOOCUS Medical Group na Dual CD19/CD20 CAR-T don DLBCL da ya sake dawowa.

An gano cewa wani mutum mai shekaru 68 daga ƙasar Ostiraliya mai suna Rodney Charles Monger yana da cutar kansa mai yaɗuwa. Lymphoma na B-Cell (DLBCL) shekaru uku da suka gabata. Don neman kulawa ta musamman, ya koma ga BIOOCUS Medical Group a watan Agusta na 2025. An yi gwajin biopsy na ƙwayoyin lymph node na mahaifa wanda ya tabbatar da kamuwa da cutar lymphoma na ƙwayoyin B-cell wanda ya samo asali daga tsakiyar ƙwayoyin cuta. Immunohistochemistry ya nuna cewa yana da CD20, CD19, da CD10, tare da yawan bayyanar Bcl-6, Bcl-2 (70%+), da c-MYC (60%+). Gwajin kwayoyin halitta ya nuna sake fasalin BCL2 ta hanyar FISH da maye gurbi a cikin kwayoyin halittar EZH2, KMT2D, TNFRSF14, NRAS, da TPMT - alamun bayyanannu na bayyanar cututtuka masu haɗari da haɗari.

Bayan shan maganin pola tare da maganin hana BTK da lenalidomide, sannan kuma maganin cutar lymphodepletion na FC, cutar ta ci gaba da zama ruwan dare. Ƙungiyar BIOOCUS Medical Group ta ba da shawarar sabuwar hanyar maganin ƙwayoyin CD19/CD20 CAR-T mai haɗaka biyu.

A ranar 8 ga Satumba, 2025, Mista Monger ya karɓi ƙwayar halittar CD19/CD20 CAR-T. Abin mamaki, bai fuskanci wata cuta ta sakin cytokine (CRS) ba kuma bai sami wata cuta ta neurotoxicity da ke da alaƙa da garkuwar jiki ba (ICANS), wanda hakan ya haifar da kyakkyawan tsari bayan an yi masa allurar da ta sa ya kasance mai natsuwa da kyakkyawan fata tun daga rana ta farko.

Sa ido kan jini a gefen jiki ya nuna faɗaɗa ƙwayoyin CAR-T mai ban sha'awa, wanda ya tabbatar da kyakkyawan tsari da yaduwa. A rana ta 4 bayan jiko, ƙwayoyin CAR19+ sun kasance 0.50% na ƙwayoyin CD3+ T (ƙimar cikakkiyar 6.04 × 10⁷/L) da ƙwayoyin CAR20+ 0.41% (4.96 × 10⁷/L). A rana ta 7, CAR19+ ya tashi zuwa 1.68% (1.40 × 10⁷/L) da CAR20+ zuwa 1.63% (1.36 × 10⁷/L). A rana ta 10, CAR19+ ya kai 31.43% na ƙwayoyin CD3+ T (ƙimar cikakkiyar 3.13 × 10⁸/L) kuma CAR20+ ya kai 32.74% (ƙimar cikakkiyar 3.26 × 10⁸/L). Tsarin kwararar jini ya kuma nuna daidaiton rarrabawa a cikin ƙananan CD4+ da CD8+ tare da ƙarfin bayyanar CAR guda biyu, yana nuna ikon maganin na haɓaka juriya da yaduwa mai ƙarfi a cikin rayuwa.

A sabon binciken da aka yi (rana ta 10), Mista Monger ya ci gaba da yin kyau a asibiti. Yana shan maganin da aka tsara masa ta hanyar amfani da acyclovir, sulfamethoxazole, orelabrutinib, lenalidomide, da kuma magungunan tallafi, tare da sa ido akai-akai kan yawan jini, aikin hanta da koda, da kuma alamun kumburi.

Tawagar BIOOCUS Medical Group ta ba da cikakken tallafi, wanda ya mayar da hankali kan marasa lafiya a ko'ina, ciki har da masauki mai daɗi, abinci mai gina jiki, taimakon sufuri, da kuma shawarwari kan tunani ga Mr. Monger da iyalinsa. Wannan tsarin ya ba shi damar mai da hankali sosai kan murmurewa.

Shari'ar Mr. Monger ta nuna misali na yiwuwar sauyi na maganin CD19/CD20 CAR-T na BIOOCUS Medical Group ga marasa lafiya da suka sake dawowa/rage ƙarfin DLBCL. Faɗaɗa ƙwayoyin CAR-T cikin sauri da ƙarfi ba tare da mummunan guba ba yana nuna kyakkyawan yanayin aminci na samfurin da kuma ƙarfin aikin hana ƙari mai ƙarfi - har ma a cikin tsofaffi marasa lafiya da ke da halayen ƙwayoyin cuta masu haɗari.